Product Information
ROZEREM 8 MG TABLET is a brand product labeled by Takeda Pharmaceuticals America, Inc., priced at $12.4169 per EA under NDC 64764080530. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Jul 22, 2005. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the ramelteon market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
8 mg/1
Manufacturer
Takeda Pharmaceuticals America, Inc.NDC
64764080530
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
RAMELTEONApproval Type
New Drug (NDA)
FDA Application
NDA021782FDA Approved
7/22/2005
TE Code
AB
On Market Since
7/22/2005
Pharmacological Classes
Price Statistics
The NADAC for ROZEREM 8 MG TABLET has been published 671 times since Nov 28, 2013, and over the history we have for it it has risen 83.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $12.4169 per EA |
|---|---|
| All-time high | $12.5063 (Aug 10, 2022) |
| All-time low | $6.7825 (Nov 28, 2013) |
| 52-week high | $12.4497 |
| 52-week low | $12.4086 |
| Median price | $12.3848 |
| Average price | $11.4534 |
| Largest weekly change | +9.9% (Apr 9, 2014) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Takeda Pharmaceuticals America, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
ramelteon market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Melatonin Receptor Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ROZEREM 8 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for ROZEREM 8 MG TABLET, manufactured by Takeda Pharmaceuticals America, Inc., is $12.4169 per EA (NDC 64764080530), effective Sep 30, 2026.
How has the price of ROZEREM 8 MG TABLET changed over time?
Over the history we have for it, the NADAC for ROZEREM 8 MG TABLET has risen 83.1%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for ROZEREM 8 MG TABLET?
Since Nov 28, 2013, the NADAC for ROZEREM 8 MG TABLET has ranged from a low of $6.7825 (Nov 28, 2013) to a high of $12.5063 (Aug 10, 2022), with a median of $12.3848 per EA.
Are there cheaper alternatives to ROZEREM 8 MG TABLET?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as ROZEREM 8 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures ROZEREM 8 MG TABLET?
ROZEREM 8 MG TABLET (NDC 64764080530) is labeled by Takeda Pharmaceuticals America, Inc., and CMS classifies it as a brand product.